Search
Brasofensine
go.drugbank.com/drugs/DB04857ExperimentalPhase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigationalMethyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. … Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].
Products: METILDOPA MK 250 MG TABLETASUrea C-14
go.drugbank.com/drugs/DB09513ApprovedInvestigationalTo detect H. pylori, urea labeled with 14C is swallowed by the patient.
Alirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of
VP025
go.drugbank.com/drugs/DB05133ExperimentalVP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. VP025 may inhibit immune system activation and protect motoneurons from injury. It also shows the abi...
Drotrecogin alfa
go.drugbank.com/drugs/DB00055ApprovedWithdrawnDrotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. … It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond.
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. … It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering.
Mannitol
go.drugbank.com/drugs/DB00742ApprovedInvestigationalthis indication under the name BRONCHITOL® by Chiesi USA Inc. … On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for
Detomidine
go.drugbank.com/drugs/DB11556InvestigationalVet approvedThis drug is prescribed by veterinarians and is marketed as _Dormosedan_. Currently, it is only approved by the FDA for use in horses but has been studied for use in other large animals.
Epinastine
go.drugbank.com/drugs/DB00751ApprovedIt has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding